USPTO serial 86645468
PREVECEUTICAL
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- COHEN, ROBERT ANDREW
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PREVECEUTICAL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ben Natter
BEN NATTER NATTER & NATTER501 Fifth AvenueNew York, NY 10017UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of Addison's Disease, Agammaglobulinemia, Alopecia Areata, Amyloidosis, Ankylosing Spondylitis, Anti-Gbm/Anti-Tbm Nephritis, Antiphospholipid Syndrome (Aps), Autoimmune Hepatitis, Autoimmune Inner Ear Disease (Aied), Axonal and Neuronal Neuropathy (Aman), Arthritis, Baló's Concentric Sclerosis (Bcs), Behcet's Disease, Bullous Pemphigoid, Cancer, Castleman Disease (Cd), Celiac Disease, Chagas Disease, Chronic Inflammatory Demyelinating Polyneuropathy (Cidp), Chronic Recurrent Multifocal Osteomyelitis (Crmo), Churg-Strauss, Cicatricial Pemphigoid/Benign Mucosal Pemphigoid, Cogan's Syndrome Cold Agglutinin Disease, Congenital Heart Block, Coxsackie Myocarditis, Crest Syndrome, Crohn's Disease, Dermatitis Herpetiformis, Dermatomyositis, Devic's Disease (Neuromyelitis Optica), Diabetes, Discoid Lupus, Dressler's Syndrome, Endometriosis, Essential Mixed Cryoglobulinemia, Eosinophilic Esophagitis (Eoe), Evans Syndrome, Fibromyalgia, Fibrosing Alveolitis, Giant Cell Arteritis (Temporal Arteritis), Giant Cell Myocarditis, Glomerulonephritis, Goodpasture's Syndrome, Granulomatosis With Polyangiitis (Gpa), Graves' Disease, Guillain-Barre Syndrome, Hashimoto's Thyroiditis, Hemolytic Anemia, Henoch-Schonlein Purpura (Hsp), Herpes Gestationis Or Pemphigoid Gestationis (Pg), Hypogammalglobulinemia, Immune Thrombocytopenic Purpura (Itp), Iga Nephropathy, Inclusion Body Myositis (Ibm), Interstitial Cystitis (Ic), Juvenile Arthritis, Juvenile Diabetes (Type 1 Diabetes), Juvenile Myositis (Jm), Kawasaki Disease, Lambert-Eaton Syndrome, Leukocytoclastic Vasculitis, Lichen Planus, Lichen Sclerosus, Ligneous Conjunctivitis, Linear Iga Disease (Lad), Lupus, Lyme Disease, Meniere's Disease, Microscopic Polyangiitis (Mpa), Mixed Connective Tissue Disease (Mctd), Mooren's Ulcer, Mucha-Habermann Disease, Multiple Sclerosis (Ms), Myasthenia Gravis, Myositis, Narcolepsy, Neuromyelitis Optica, Neutropenia, Ocular Cicatricial Pemphigoid, Optic Neuritis, Palindromic Rheumatism (Pr), Pandas (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcus), Paraneoplastic Cerebellar Degeneration (Pcd), Paroxysmal Nocturnal Hemoglobinuria (Pnh), Parry Romberg Syndrome, Parsonnage-Turner Syndrome, Pars Planitis, Pemphigus, Pernicious Anemia (Pa), Peripheral Neuropathy, Perivenous Encephalomyelitis, Poems Syndrome, Polyarteritis Nodosa, Polymyalgia Rheumatic, Polymyositis, Postmyocardial Infarction Syndrome, Postpericardiotomy Syndrome, Progesterone Dermatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Psoriatic Arthritis, Idiopathic Pulmonary Fibrosis, Pyoderma Gangrenosum, Pure Red Cell Aplasia (Prca), Raynaud's Phenomenon, Reactive Arthritis, Reflex Sympathetic Dystrophy, Reiter's Syndrome, Relapsing Polychondritis, Restless Legs Syndrome (Rls), Retroperitoneal Fibrosis, Rheumatic Fever, Rheumatoid Arthritis (Ra), Sarcoidosis, Schmidt Syndrome, Scleritis, Scleroderma, Sjogren's Syndrome, Sperm and Testicular Autoimmunity, Stiff Person Syndrome (Sps), Subacute Bacterial Endocarditis (Sbe), Susac's Syndrome, Sympathetic Ophthalmia (So), Takayasu's Arteritis, Temporal Arteritis/Giant Cell Arteritis, Thrombocytopenic Purpura (Ttp), Tolosa-Hunt Syndrome (Ths), Transverse Myelitis, Type 1 Diabetes, Ulcerative Colitis (Uc), Undifferentiated Connective Tissue Disease (Uctd), Uveitis, Vasculitis, Vitiligo and Wegener's Granulomatosis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cornerstone Global Partners Inc.
- Other trademarks owned by PREVECEUTICAL MEDICAL INC.
- Other trademarks owned by Cornerstone Global Partners Inc.
- Other trademarks in Class 005
- Similar marks named PREVECEUTICAL
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 27, 2017 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 27, 2017 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 27, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 25, 2016 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 25, 2016 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 25, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 30, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 30, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 24, 2016 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 26, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 1, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 1, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 11, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 27, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 26, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 23, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 23, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 11, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 1, 2015 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jun 24, 2015 | ALIE | ASSIGNED TO LIE | — |
| Jun 16, 2015 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jun 4, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 2, 2015 | NWAP | NEW APPLICATION ENTERED | — |